Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Stu
3 hours ago
- #Plaque Psoriasis
- #Icotrokinra
- #Phase 3 Trial
- The study ICONIC-LEAD is a Phase 3 trial focusing on icotrokinra, an oral peptide for moderate-to-severe plaque psoriasis in adults.
- It examines maintenance of response through randomized treatment withdrawal, assessing retreatment outcomes for responders.
- The research highlights the potential of targeted oral therapies in managing psoriasis and evaluating long-term efficacy.